64 results about "Cannabigerol" patented technology

The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.

The invention is a product and a process wherein cannabinoids such as Medicinal Δ9-THC and / or other substances associated with medicinal cannabis, including yet not necessarily limited to cannbidiols, cannabigerol are contained or processed into foodstuffs or medicinal compounds in controlled ways and with specific characteristics. First a medicinal substance with a known about of medicinal cannabis is mixed into a foodstuff such that the medicinal cannabis is distributed uniformly in the foodstuff. Foodstuffs consistent with this invention include baked goods, hard candies, ice cream, bases, ice cream, and yogurt. The product is characterized by a controlled amount of cannabinoids per unit volume of the foodstuff. Another provision of the invention is providing controlled amounts or ratios of Δ9-THC as compared to CBD in a foodstuff.

The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.

The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.

One or more cannabinoids and / or terpenes in combination with psilocybin and / or psilocin may be used in the prevention or treatment of psychological or brain disorders. The one or more cannabinoids may be taken from the group of cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA).

The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.

The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.

The invention discloses a clathrate containing non-psychoactive cannabinoid and a preparation method of the clathrate. The preparation method includes sequentially subjecting hemp extract to dissolution by organic solvents, clathration by clathration agents, decomposition and impurity removal by water-organic solvents, and vacuum drying and precipitation. The clathrate can completely remove psychoactive components such as tetrahydrocannabinol (THC) and delta 9-tetrahydrocannabivarin (THCV), and effectively enrich non-psychoactive components with the total content of more than 50%, such as cannabidiol (CBD), cannabigerol (CBG) and cannabichromene (CBC). The preparation method has the advantages of simple process and easiness in industrialization.

The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.

The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).

The invention relates to a method for simultaneously separating secondary cannabidiol and cannabigerol. The method comprises the following steps: sufficiently oscillating a solvent system, allowing the solvent system to stand, and separately collecting an upper phase and a lower phaser; dissolving an industrial hemp full-spectrum essential oil sold in the market into the upper phase, performing separation by using high-speed countercurrent chromatography by taking the upper phase as an immobile phase and the lower phase as a mobile phase so as to respectively obtain a mixed liquid of secondarycannabidiol and the mobile phase and a mixed liquid of cannabigerol and the mobile phase, and removing the mobile phase, so as to obtain the secondary cannabidiol and the cannabigerol. By adopting the method, a high-speed countercurrent chromatography technique is adopted for a first time to simultaneously separate and purify secondary cannabidiol (CBDV) of which the purity is greater than 98% and cannabigerol of which the purity is greater than 97% from the industrial hemp full-spectrum essential oil.

The invention discloses a saccharomyces cerevisiae strain with high yield of cannabigerol and a construction method and application thereof. The saccharomyces cerevisiae strain with high yield of cannabigerol is obtained by inserting TKS and OAC enzymes into a saccharomyces cerevisiae strain A capable of producing the cannabigerol through gene editing technology. According to the invention, the gene editing technology is used for regulating and controlling the gene copy numbers of the 2, 4-olivetol synthase TKS and the 2, 4-olivetolic acid synthase OAC, and the accumulation amount of OLA is increased. Finally, the metabolic flux of the cannabigerolic acid synthesis precursors (GPP and OLA) is balanced, and the purpose of high yield of cannabigerolic acid is achieved.

In one aspect, the invention provides a method for preventing the transmission of HIV from one individual to another. In accordance with the method, a pharmacologicallyacceptable composition including at least one resorcinol derivative compound and / or cannabinoid (e.g., cannabdol derivatives, Delta8-THC derivatives, cannabichromene derivatives, cannabidiol derivatives, cannabigerol derivatives) (including combinations thereof) is administered topically to a first individual harboring HIV, or to a second individual at risk of infection with HIV, proximate in time with contact between the first individual and the second individual. The invention also provides topical formulations of at least one resorcinol and / or cannabinoid and water insoluble polymers as hydrogels.

The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and / or purified from cannabis plant extracts.